

## CLAIMS

1. A pharmaceutical composition for oral administration comprising an active substance having a food effect, in  
5 combination with a lipid material comprising membrane lipids, characterised in showing a reduced food effect.
2. The pharmaceutical composition according to claim 1, wherein the content of membrane lipids is not less than 3  
10 % by weight of the lipid material.
3. The pharmaceutical composition according to claim 1 or 2, wherein the membrane lipids contain digalactosyl-diacylglycerol in an amount not less than about 0.5 % by  
15 weight of the lipid material.
4. The pharmaceutical composition according to any of claims 1-3, wherein the lipid material comprises a fractionated cereal oil, preferably from oats.  
20
5. The pharmaceutical composition according to any of claims 1-4, wherein the lipid material comprises non-polar lipids.
- 25 6. The pharmaceutical composition according to any of the preceding claims, wherein the composition comprises the active substance dissolved or dispersed in solid lipid particles with a diameter of not more than 20  $\mu\text{m}$ .
- 30 7. A pharmaceutical composition for oral administration comprising from 0.5 to 12 % by weight of the composition, preferably 1 to 8 %, of isotretinoin, and a lipid material comprising from 2 % to 60 % by weight of membrane lipids, and from 30 to 98 % by weight of non-polar lipids,  
35 calculated on the lipid material.
8. A pharmaceutical composition for oral administration comprising from 0.1 to 20 % by weight of an immunosuppressant, from 1 % to 40 % by weight of membrane  
40 lipids, and from 5 to 40 % by weight of monoglycerides, calculated on the composition.
9. A pharmaceutical composition for oral administration comprising up to about 50 % by weight of an antiviral,  
45 from about 10 % to about 70 % by weight of membrane lipids, and from about 10 % to about 70 % by weight of monoglycerides, calculated on the composition.

10. The pharmaceutical composition according to any of the preceding claims, wherein the lipid material comprises about 3 % to about 60 % by weight of monoglycerides.

5 11. The pharmaceutical composition according to any of claims 8-10, wherein the monoglycerides comprise medium chain monoglycerides.

10 12. The pharmaceutical composition according to any of the preceding claims, wherein the lipid material comprises at least 10 % by weight of di- and triglycerides or a mixture thereof.

15 13. The pharmaceutical composition according to any of the preceding claims comprising in addition a polar solvent.

14. A pharmaceutical composition comprising solid lipid particles with a diameter of not more than about 20  $\mu\text{m}$ , comprising

20 a) an active substance, dissolved or dispersed in said lipid particles, and  
b) a lipid material comprising membrane lipids.

25 15. The pharmaceutical composition according to any of the preceding claims, showing a reduced food effect of at least 25 %.

16. The pharmaceutical composition according to any of the preceding claims, having a food effect less than 20 %.

30 17. Use of a lipid material comprising membrane lipids for the manufacture of a pharmaceutical composition according to any of the preceding claims having a reduced food effect.

35

40

45

50